Overview An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis Status: RECRUITING Trial end date: 2027-06-01 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.Phase: PHASE1 Details Lead Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology